Robert Mate
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Nicotinic Acetylcholine Receptors Study, Receptor Mechanisms and Signaling, Pharmacological Receptor Mechanisms and Effects, Alzheimer's disease research and treatments, Microbial Natural Products and Biosynthesis
Most-Cited Works
- → Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor(2010)184 cited
- → Discovery of the first antibacterial small molecule inhibitors of MurB(2003)88 cited
- → Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials(2004)42 cited
- → Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists(2013)24 cited
- → Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship(2016)18 cited
- → Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates(2020)15 cited
- → BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia(2017)14 cited
- → Development of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists(2016)12 cited
- → Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR(2017)9 cited
- → Novel tricyclic diamines 2. Synthesis of 1,7-diazaisoadamantane, 1,5-diazaisoadamantane and 1,6-diazahomobrendane(2018)8 cited